Kornimate/medical-research-clean huggingface dataset:
evaluation study of the effects of sulphurous water in the treatment of knee osteoarthritis.

Conditions: KNEE OSTEOARTHRITIS

Summary: the objectives are to evaluate the effects of immersion bath with sulphurous water in pain, joint mobility and quality of life in patients with knee osteoarthritis. patients will undergo three weekly baths in sulphurous water and not sulphurous, twenty minutes each, for ten weeks. the expected results are: reduction of pain, improved range of motion of the lower limbs with consequent increase in muscle mass improvement in postural balance, which will come due to the reduction of pain and improvement movements of the lower limbs; greater independence in performing the activities of daily living, better quality of life.

the baths were performed in individual tubs, properly disinfected, supplied with thermal water and sulphurous thermal sulphurous not at a temperature 37-39 ° c, which encompass the optimum temperatures for therapeutic bath. the baths lasted for 20 minutes. the subjects drank two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water. treatment consisted of 30 individual treatment sessions, three times a week, lasting twenty minutes each session, for ten weeks. the experiment was performed at the therms antonio carlos, institution belonging to the municipality of poços de caldas, minas gerais, brazil.

Eligibility criteria:
inclusion criteria: we selected individuals of both genders, diagnosed with osteoarthritis of the knee according to the classification criteria of the american college of rheumatology (acr) only grades i to iii chronic pain at some knees, for a minimum period of three months. exclusion criteria: * patients with fibromyalgia; * individuals with respiratory diseases; * rheumatic diseases autoimmune inflammatory; * patients with uncontrolled thyroidopathies; * patients with injuries or amputations of lower limbs; * patients with psychiatric disorders or cognitive; * patients with a history of osteoporotic fracture; * patients with malignant * patients with infectious processes; * patients pregnant; * individuals who failed to enter the baths due to physical limitations; * were also excluded those who were engaged in other forms of treatment or using painkillers and anti-inflammatory drugs for other diseases. note: were not excluded participants who were diagnosed with osteoarthritis in the spine, herniated, or degenerative disc protrusions.

Keywords: knee osteoarthritis balneotherapy sulphurous waters womac lequesne health assessment questionnaire short form - 36 vas
diagnosis of superficial lymphadenopathy

Conditions: Lymphadenopathy; ULTRASOUND

Summary: the purpose of this study is to study the application of ceus and smi technology in superficial lymph node lesions (metastasis, lymphoma, inflammation, etc.), and to provide some diagnostic ideas for non-invasive diagnosis of lymph node lesions.

ceus and smi technology were used to evaluated the superficial lymph node lesions (metastasis, lymphoma, inflammation, etc.), and to provide some diagnostic ideas for non-invasive diagnosis of lymph node lesions.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old and ≤ 80 years old; 2. patients with enlarged lymph nodes detected by ultrasound; 3. no contraindications such as hypersensitivity to contrast-enhanced ultrasound; 4. voluntarily enrolled in this research project exclusion criteria: * the patient's position cannot be matched during ultrasound examination * treatment history of lesion area: operation, radiotherapy, intervention, etc ③ patients without informed consent ④ lack of clinical data (no effective images such as two-dimensional ultrasound, color doppler, contrast-enhanced ultrasound, micro blood flow imaging, or poor image quality, unable to analyze, unknown pathological results, etc.) ⑤ lack of follow up information
convalescent plasma to limit sars-cov-2 associated complications

Conditions: SARS-CoV 2

Summary: to assess the efficacy and safety of human coronavirus immune plasma (hcip) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.

the purpose of this randomized, double-blind, controlled, phase 2 trial is to evaluate the efficacy of treatment with hcip in reducing hospitalization and death prior to hospitalization among outpatient adults who have rna detection test-confirmed covid-19 and have developed any symptoms of covid-19 including but not limited to fever, cough, or other covid associated symptoms like anosmia. ambulatory/outpatient adults subjects 18 years of age or older, regardless of risk factors for severe illness may participate. a total of approximately 1344 eligible subjects stratified with a target goal (but not binding) of 50:50 in the \<65 vs ≥ 65 age range will be randomized in a 1:1 ratio to receive either hcip or control plasma.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * competent and capable to provide informed consent * • positive molecular test for presence of sars-cov-2 in fluid collected by saliva for antigen, oropharyngeal or nasopharyngeal swab * experiencing any symptoms of covid-19 including but not limited to fever(t\> 100.5º f), cough, or other covid associated symptoms like anosmia * ≤ 8 days since the first symptoms of covid-19 * ≤ 8 days since first positive sars-cov-2 rna test * able and willing to comply with protocol requirements listed in the informed consent exclusion criteria: * hospitalized or expected to be hospitalized within 24 hours of enrollment * psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance * history of prior reactions to transfusion blood products * inability to complete therapy with the study product within 24 hours after enrollment * receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). steroid treatment at any time does not affect study eligibility

Keywords: covid-19
the effect of metformin on reducing lupus flares

Conditions: Systemic Lupus Erythematosus

Summary: this is a multicenter, randomised, double-blind placebo controlled trial on the efficacy and safety of add-on metformin to conventional immunosuppressants in systemic lupus erythematosus (sle). the purpose of this study is to evaluate: 1) the effect of metformin on reducing disease flares; 2) the influence of metformin on corticosteroid sparing effect; 3) the influence of metformin on body mass index (bmi); 4) the safety of metformin.


Eligibility criteria:
inclusion criteria: * willingness of the subject to participate in the study, proven by signing the informed consent; * systemic lupus erythematosus (sle), as defined by meeting at least 4 of 11 classification criteria of american college of rheumatology for the classification of systemic lupus erythematosus, either sequentially or coincidentally. the 4 criteria doesn't need to be present at the time of study enrollment; * the course of sle longer than1 year; and there is a clear record of disease flares in the past 1 year with prednisone more than 20mg/day; * patients with mild/moderate disease activity (score≤ 6 at screening on sledai); no british isles lupus assessment group (bilag) a or no more than one b; * a stable treatment regimen with fixed doses of prednisone (≤ 20mg/day), antimalarial, or immunosuppressive drugs (azathioprine/ mycophenolate mofetil/ methotrexate/ ciclosporin/ leflunomide/ thalidomide) for at least 30 days. exclusion criteria: * patients who are unwilling to sign the inform consent; * alanine aminotransferase (alt)/ aspartate aminotransferase (ast) \> 2 times upper normal limits; creatinine clearance rate \< 60ml/min; * patients who used cyclophosphamide 6-months before screening; used biological agents 12-months before screening; * previous exposure of metformin within 30 days before screening; or previous history of intolerant to metformin; * patients who diagnosed of diabetes mellitus; * pregnancy or lactation.

Keywords: metformin systemic lupus erythematosus
progressive resistance training in acute spinal cord injury

Conditions: Spinal Cord Injuries; Quadriplegia; Trauma, Nervous System; Paralysis; Spinal Cord Diseases

Summary: muscle weakness is one of the most common and debilitating symptoms following a spinal cord injury (sci). strength training is recommended as an effective means to increase muscular strength and improve function for individuals with long term sci. in contrast, the strength training guidance for those with a recent (\<1 year) sci is lacking. therefore, this study aims to investigate the feasibility of a method of upper limb strengthening - progressive resistance training (prt) and its impact upon muscle strength and function.

the trial and recruitment will be conducted at the queen elizabeth national spinal injuries unit (qensiu), glasgow. individuals with tetraplegia and upper limb weakness will be randomly allocated to receive either a tailored progressive resistance training (prt) programme alongside usual care or usual care alone. up to 30 participants admitted to the qensiu will be recruited to the study. they will be randomised to the intervention or control group. the intervention group will receive 8 weeks of prt. an upper limb functional goal will be identified through discussion with the researcher and the participant. prt will be individually tailored to target two muscle groups which contribute to achieving this goal. for each muscle group 3 sets of 8-10 repetitions will be carried out, resistance will be applied using wrist weights, free weights or resistance bands as required. measurements of muscle strength and function will be assessed prior to, and following the study. outcome measures: manual muscle testing, handheld dynamometry, the spinal cord independence measure, the action research arm test.

Eligibility criteria:
inclusion criteria: * acquired non-progressive sci - traumatic, spinal cord stroke, surgical injury * within 2 weeks of being identified as medically stable by the treating consultant * over 18 years old * individuals classified with complete or incomplete tetraplegia (c1-c8), graded a-d according to the american spinal injury association (asia) scale * bilateral or unilateral partial paresis of at least two muscle groups of the upper limb * manual muscle testing grade 2-4 strength in target muscle groups * able to tolerate sitting upright in a wheelchair for at least 2 hours exclusion criteria: * acute condition impairing a participant's ability to perform prt (e.g. fracture) * proven or suspected neuromuscular weakness affecting the upper limbs due to another condition (e.g. stroke or guillain-barré syndrome) * unable to follow instructions in english * symptomatic cardiac disease * ventilator dependency * severe spasticity * uncontrolled autonomic dysreflexia * likely to be discharged before the end of the intervention

Keywords: spinal cord injury progressive resistance training physical therapy physiotherapy strength training
focal muscular vibration in patients with severe acquired brain injury

Conditions: Brain Injuries; Spasticity, Muscle

Summary: severe acquired brain injury (sabi) is a group of disorders that cause long-term disability. rehabilitation is essential to counteract bed immobilization, muscle failure, pain, and sensory deficits that can affect the clinical and rehabilitation pathway of these patients. focal muscle vibration (fmv) is a tool that uses low-amplitude, high-frequency vibrations that when applied to muscle-tendon units. this technique, administered at specific frequencies, amplitudes and durations, can generate action potentials of the same frequency as the stimulus applied to the muscle or tendon. this makes it possible to activate selected afferent fibers and stimulate targeted brain areas with persistent effects over time (long-term potentiation). regarding the effect of counteracting vibration spasticity, fmv is able to inhibit the reflex arc and induce reciprocal inhibition of functional agonist muscle. in addition, the strong proprioceptive stimulus generated by vibration is able to reach the primary motor and somatosensory cortex, enhancing cortical mechanisms that regulate co-contraction between agonist and antagonist muscles, thereby reducing muscle tone and joint stiffness. in many studies, this technique has been shown to be effective in reducing pain and joint stiffness by improving muscle contraction and motor control.

the present study aims to analyze the effects of focal muscle vibration in patients with sabi. this study is innovative for the setting, as it will take place for the first time within a neurorehabilitation hospital ward, for the intensity of the treatment as patients will undergo daily treatment sessions, for longer periods than protocols so far in the scientific literature. finally, the cortical effects of the vibratory stimulus will be analyzed through the analysis of cortical neurophysiological correlates

Eligibility criteria:
inclusion criteria: * age between 18-75 years * picture of subacute sabi (20 days to 6 months after the acute event), of any etiology (traumatic, vascular, metabolic) * presence of spasticity in the affected limb as assessed by the modified ashwort scale (mas) ≥ 1+ exclusion criteria: * recent treatment with botulinum toxin (within 3 months); * ongoing treatment with systemic muscle relaxant drugs (baclofen, tizanidine, benzodiazepines); * deep vein thrombosis; * central/peripheral accesses ipsilateral to the limb(s) to be treated; * oncological diseases; * epilepsy; * open skin lesions or local infections.
dendritic cell immunotherapy for mesothelioma

Conditions: Mesothelioma

Summary: this study is to evaluate the overall survival (os) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with mesopher plus best supportive care (bsc) compared to bsc alone.

this is an open-label, randomized phase ii/iii study in adult subjects with mesothelioma to evaluate the efficacy and anti-tumor activity of dendritic cell immunotherapy with mesopher plus best supportive care compared to best supportive care alone. the safety, tolerability, quality of life and immunogenicity of mesopher will also be evaluated. the study includes a screening phase, a 7 month open-label treatment phase during which subjects visit the study center for administration of study drug and follow-up evaluations. an end-of-study (eos) visit will be performed after completion of the study, after which data on survival, subsequent therapies and response to these therapies will be collected. a target of 230 subjects satisfying all study criteria, will be randomized to receive either dendritic cell therapy plus best supportive care (arm a) or best supportive care alone (arm b). subjects in arm a will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. these dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (pheralys). treatment with autologous dendritic cells loaded with pheralys is called mesopher. the treatment with mesopher will start within 9 to 13 weeks after the last dose of chemotherapy. subjects will receive 3 bi-weekly injections with mesopher in addition to bsc. in case of stable disease or partial/complete response, an additional 2 injections will be given at weeks 18 and 30. subjects will be administered with a maximum of 5 doses of mesopher. subjects in arm b will be treated with best supportive care according to the discretion of the local investigator.

Eligibility criteria:
subjects will only be included with a histologically confirmed diagnosis of pleural malignant mesothelioma, who are non-progressive after 4 to 6 cycles with first line chemotherapy with antifolate/platinum.

Keywords: denim
yoga for painful chemotherapy-induced peripheral neuropathy: a pilot, randomized-controlled study

Conditions: Chemotherapy-induced Peripheral Neuropathy; Yoga; Chronic Pain; Neuropathic Pain

Summary: this research study will examine the feasibility of conducting an eight-week yoga intervention for individuals with chronic painful chemotherapy-induced peripheral neuropathy.

this research study will examine the feasibility of conducting an eight-week yoga intervention for individuals with chronic painful chemotherapy-induced peripheral neuropathy. the investigators will also explore participants' perceptions of acceptability and satisfaction with the yoga intervention. lastly, the investigators will examine changes in chemotherapy-induced peripheral neuropathy severity, physical function, sleep-related impairment, fatigue, anxiety, depression, and pain following the eight-week yoga intervention.

Eligibility criteria:
inclusion criteria: -≥18 years of age, * self-report ≥ 4/10 worst chemotherapy-induced peripheral neuropathy pain over the past week, * at least three months post neurotoxic chemotherapy completion * signed informed consent, * willingness to participate in all study activities * speak/read english exclusion criteria: * prognosis of less than three months, * documented peripheral neuropathy due to other causes (e.g., diabetes), * planned receipt of neurotoxic chemotherapy during the study period, * practice yoga \>45 minutes per week over the past six months, * diagnosis or documented recent history of significant psychiatric comorbidity (i.e., psychosis, suicidal ideation, or substance abuse) * clinician deems that the patient is physically/functionally unable to participate in a yoga program

Keywords: chemotherapy-induced peripheral neuropathy yoga chronic pain neuropathic pain
a research study comparing how well different doses of the medicine nn0519-0130 help people with excess body weight lose weight

Conditions: Obesity

Summary: this study will look at how a new medicine called nnc0519-0130 helps people with excess body weight lose weight. the study will test up to 6 different doses of nnc0519-0130. participants will take 1-2 injections once a week. the study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. the study will last for about 42 weeks.


Eligibility criteria:
inclusion criteria: * female of non-childbearing potential, or male. a. for us only: female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency at least 2 months prior to screening and willingness to continue using it through-out the study, or male. * age 18-75 years (both inclusive) at the time of signing the informed consent. * history of at least one self-reported unsuccessful dietary effort to lose body weight. * a) bmi ≥ 27.0 kg/m2 with the presence of at least one weight-related co-morbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. * b) bmi ≥ 30.0 kg/m2. exclusion criteria: * hba1c greater than equal to 6.5% (48 millimoles per mole (mmol/mol)) as measured by the central laboratory at screening. * history of type 1 or type 2 diabetes mellitus. * treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening.
prospective randomized controlled trial for pain relief after office ureteral stent removal

Conditions: Pain; Urinary Stone; Urinary Calculi

Summary: this is a prospective randomized double-blind controlled trial assessing the benefits of intramuscular ketorolac before or immediately after office ureteral stent removal.

patients who are undergoing cystoscopy with ureteral stent removal at the university of texas southwestern medical center and have no contraindications to receiving ketorolac will be eligible. patients will be randomized to receive either a 1 ml injection of ketorolac tromethamine or 1 ml injection of normal saline (0.9%) as the control arm. ketorolac is a member of the pyrrolo-pyrrole group of non steroid anti inflammatory drugs. the mechanism of action of ketorolac, like that of other nsaids, is not completely understood but may be related to prostaglandin synthetase inhibition. the peak analgesic effect occurs within 2-3 hours. if no contraindications exist, ketorolac can be safely given to patients of any age in the 30 mg intramuscular formulation if given as a one time dose according to the package insert. normal saline contains 0.9% of sodium chloride in each ml. like ketorolac, it is a clear solution and given that there are no major side effects of normal saline it is a good control for our study. it is packaged in a single dose vial that contains 100 ml. it is preservative free and stored at room temperature (20-25°c). local pain at the injection site may occur, temporarily. the investigators will specifically look at pain scores before and after stent removal as well as narcotic medication use, telephone calls and/or emergency room visits for pain. based on the rate of renal colic from our quality improvement project and prior work, the investigators calculated the maximum number of local subjects to be consented for this study to be n=116 (see biostatistics section). the study is expected to last 6 months.

Eligibility criteria:
inclusion criteria: * patients 18 to 79 who have undergone a cystoscopy with indwelling double-j ureteral stent placement at clements university hospital and are presenting to the office for cystoscopy and stent removal. exclusion criteria: * egfr \<50 * any active or history of peptic ulcer disease or gi bleeding * bleeding disorder, suspected of confirmed cerebrovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis * concurrent use of aspirin 325mg, wafarin, rivaroxaban, apixaban, clopidogrel, or heparin * allergic reaction to nsaids * concurrent use of other nsaids within 24 hours * pregnancy (ketorolac contraindicated in this population) * recent myocardial infarction (mi)

Keywords: stent removal, pain, kidney stones
incidence of postoperative residual neuromuscular blockade in the era of sugammadex

Conditions: Postoperative Residual Curarization

Summary: this study is a prospective observational study. a total 52 patients will be included in this study. we will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.


Eligibility criteria:
inclusion criteria: * patients undergoing elective surgery under general anesthesia. * american society of anesthesiologists grade 1, 2, or 3. * aged \>18 years exclusion criteria: * refusal to participate in the study * body mass index \ 35 kg/m2 * history of neuromuscular disease. * history of allergy to neuromuscular blockade * scheduled to transfer to the intensive care unit